Skip to main
NRXP

NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target

NRX Pharmaceuticals (NRXP) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NRX Pharmaceuticals is well positioned with multiple shots on goal and increasing regulatory clarity for their CNS portfolio. With the potential for both branded and generic ketamine pathway approvals, as well as expanding their NRX-101 program into a broader neuroplastic platform, the company has shown promising progress in their clinical trials. Additionally, their recent acquisition and expansion of HOPE Therapeutics supports their long-term commercialization strategy, making NRX Pharmaceuticals a strong candidate for future growth and success in the biotech market.

Bears say

NRX Pharmaceuticals is facing significant risks related to its clinical development, regulatory approval, and commercial execution for its novel bipolar depression drugs, NRX-100 and NRX-101. The company's valuation is based on optimistic assumptions, such as a high probability of success and significant revenues from future general use. However, potential challenges such as financing and dilution risks could hinder the achievement of its $45 price target. Overall, the company's stock is a high-risk investment with uncertainties surrounding its potential success in the market.

NRX Pharmaceuticals (NRXP) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NRX Pharmaceuticals (NRXP) Forecast

Analysts have given NRX Pharmaceuticals (NRXP) a Strong Buy based on their latest research and market trends.

According to 4 analysts, NRX Pharmaceuticals (NRXP) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NRX Pharmaceuticals (NRXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.